 Home > Biochemistry News > Biotechnology News > Innovative HIV combination therapy reaches two phase 3 clinical trial endpoints to support the submission of regulatory applications

Innovative HIV combination therapy reaches two phase 3 clinical trial endpoints to support the submission of regulatory applications

 Last Update: 2021-12-04
 Source: Internet
 Author: User

Tags

lyrica show drug test

long trichomoniasis

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On October 25, 2021, Merck & Co.

These patients obtained virological suppression after receiving different antiretroviral treatment regimens (ART), or a combination of bictegrair/emtricitabine/tenofovir (BIC/FTC/TAF), a common drug for the treatment of AIDS

Both trials reached the primary efficacy endpoint.

Doravirine is an innovative once-a-day oral non-nucleoside reverse transcriptase inhibitor developed by Merck

With the development of anti-HIV therapy, most HIV-infected people have been able to achieve the effect of controlling the virus level by taking daily anti-viral therapy

▲The molecular structure of Islatravir (picture source: Edgar181, Public domain, via Wikimedia Commons)

Preclinical studies have shown that Islatravir can inhibit the function of HIV reverse transcriptase through a variety of mechanisms.

Reference materials:

[1] Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express Innovative HIV Combination Therapy Reached the Endpoints of Two Phase 3 Clinical Trials and Supported the Submission of Regulatory Applications

11-16

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Innovative HIV combination therapy reaches two phase 3 clinical trial endpoints to support the submission of regulatory applications

Related Articles

Express Innovative HIV Combination Therapy Reached the Endpoints of Two Phase 3 Clinical Trials and Supported the Submission of Regulatory Applications